New combo therapy for tough prostate cancer shows promise in early trial

NCT ID NCT03737370

Completed Disease control Sponsor: Tufts Medical Center Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 11, 2026 · Updated 26 times

Summary

This early-phase study tested a combination of two treatments—split-dose chemotherapy (docetaxel) and a targeted radiation drug (radium-223)—in 43 men with advanced prostate cancer that no longer responds to hormone therapy. The main goal was to find the safest dose and understand side effects. Results help guide future research on managing this hard-to-treat cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Henry Ford Health System

Detroit, Michigan, 48202, United States
Lahey Hospital & Medical Center

Boston, Massachusetts, 01805, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Tufts Medical Center

Boston, Massachusetts, 02111, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATE RESISTANT PROSTATE CANCER